|Awarded On||September 14, 2022|
|Title||In vivo Akt Analysis via Chemical Genetics and Nanoparticle-mediated Probe Delivery|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||Texas Tech University|
|Principal Investigator/Program Director||Degeng Wang|
*Pending contract negotiation
Protein kinases are key cancer therapy targets. But kinase studies are hindered by lack of powerful in vivo analysis methods. We address this challenge with Akt1 and Akt2 as initial model. Though sharing high sequence homology, they display functional different in metastasis. In colon cancer, Akt2 is a strong promoter of metastasis, but Akt1 is an inhibitor. Understanding the difference begs for better analysis methods. Previously, we have combined the chemical genetic method developed by Dr. Kevan Shokat and nanoparticle intracellular delivery of the bulky ATP analog N6-Benzyl-ATP-gamma-S (A*TP-gamma-S). According to the Shokat method, we mutated the gate-keeper Methionine to Glycine, creat...